Wall Street brokerages predict that NeoGenomics, Inc. (NASDAQ:NEO) will report $0.05 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for NeoGenomics’ earnings. The highest EPS estimate is $0.08 and the lowest is $0.04. NeoGenomics also reported earnings per share of $0.05 during the same quarter last year. The business is expected to issue its next quarterly earnings results on Wednesday, February 20th.
On average, analysts expect that NeoGenomics will report full year earnings of $0.18 per share for the current fiscal year, with EPS estimates ranging from $0.17 to $0.19. For the next year, analysts anticipate that the company will report earnings of $0.24 per share, with EPS estimates ranging from $0.22 to $0.28. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow NeoGenomics.
NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, October 30th. The medical research company reported $0.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.03. The firm had revenue of $69.10 million during the quarter, compared to analyst estimates of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 2.63%. The business’s revenue was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.01 EPS.
In other NeoGenomics news, Director Kevin C. Johnson sold 66,007 shares of NeoGenomics stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $17.03, for a total value of $1,124,099.21. Following the completion of the sale, the director now owns 97,873 shares in the company, valued at approximately $1,666,777.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lynn A. Tetrault sold 13,000 shares of the firm’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $16.00, for a total transaction of $208,000.00. Following the completion of the transaction, the director now directly owns 40,234 shares in the company, valued at $643,744. The disclosure for this sale can be found here. In the last three months, insiders sold 4,994,643 shares of company stock valued at $83,771,998. Insiders own 12.20% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Glenmede Trust Co. NA bought a new stake in shares of NeoGenomics during the 3rd quarter valued at approximately $114,000. Cubist Systematic Strategies LLC bought a new stake in shares of NeoGenomics during the 2nd quarter valued at approximately $171,000. AMP Capital Investors Ltd bought a new stake in NeoGenomics during the 2nd quarter worth approximately $178,000. Prudential Financial Inc. bought a new stake in NeoGenomics during the 3rd quarter worth approximately $224,000. Finally, PNC Financial Services Group Inc. bought a new stake in NeoGenomics during the 2nd quarter worth approximately $272,000. 83.61% of the stock is currently owned by hedge funds and other institutional investors.
NeoGenomics stock traded down $0.59 on Friday, reaching $14.19. 970,390 shares of the stock were exchanged, compared to its average volume of 645,419. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 236.50 and a beta of -0.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.13 and a quick ratio of 3.98. NeoGenomics has a twelve month low of $7.08 and a twelve month high of $19.04.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Recommended Story: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.